Haruya Okamoto

Kyoto, 6060823, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines.

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines.

Journal: Chemical & pharmaceutical bulletin

Published: March 18, 2026

Pseudoprogression of bladder extramedullary disease of multiple myeloma following the treatment with elranatamab, an anti-BCMA/CD3 bispecific antibody.

Pseudoprogression of bladder extramedullary disease of multiple myeloma following the treatment with elranatamab, an anti-BCMA/CD3 bispecific antibody.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: March 01, 2026

Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid-derived suppressor cells by myeloma cells.

Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid-derived suppressor cells by myeloma cells.

Journal: British journal of haematology

Published: February 12, 2026

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

Journal: British journal of haematology

Published: February 02, 2026

Multistep molecular trajectory of monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells.

Multistep molecular trajectory of monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells.

Journal: Biochemical and biophysical research communications

Published: October 31, 2025

Case Report: Immunophenotypically diverse immature patterns, including variable TdT expression, in aggressive B-cell lymphomas and leukemia with MYC rearrangement.

Case Report: Immunophenotypically diverse immature patterns, including variable TdT expression, in aggressive B-cell lymphomas and leukemia with MYC rearrangement.

Journal: Frontiers in oncology

Published: August 12, 2025

Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.

Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.

Journal: Cureus

Published: July 29, 2025

Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)

Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 02, 2025

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Journal: Leukemia & lymphoma

Published: March 26, 2025

Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.

Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.

Journal: Leukemia & lymphoma

Published: March 25, 2025

Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated by Paraneoplastic Encephalitis.

Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated by Paraneoplastic Encephalitis.

Journal: Internal medicine (Tokyo, Japan)

Published: February 02, 2025

Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities.

Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities.

Journal: Leukemia

Published: August 24, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026